Label-free determination of prostate specific membrane antigen in human whole blood at nanomolar levels by magnetically assisted surface enhanced Raman spectroscopy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F17%3A73584400" target="_blank" >RIV/61989592:15110/17:73584400 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61989592:15310/17:73584400 RIV/61388963:_____/18:00492495 RIV/00216208:11310/18:10370243

Výsledek na webu

<a href="https://www.sciencedirect.com/science/article/pii/S0003267017311480" target="_blank" >https://www.sciencedirect.com/science/article/pii/S0003267017311480</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.aca.2017.10.008" target="_blank" >10.1016/j.aca.2017.10.008</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Label-free determination of prostate specific membrane antigen in human whole blood at nanomolar levels by magnetically assisted surface enhanced Raman spectroscopy

Popis výsledku v původním jazyce

Prostate cancer is one of the most common cancers among men and can in its later stages cause serious medical problems. Due to the limited suitability of current diagnostic biochemical markers, new biomarkers for the detection of prostate cancer are highly sought after. An ideal biomarker should serve as a reliable prognostic marker, be applicable for early diagnosis, and be applicable for monitoring of therapeutic response. One potential candidate is glutamate carboxypeptidase II (GCPII), also known as prostate specific membrane antigen (PSMA), which has a promising role for direct imaging. GCPII is considerably over-expressed on cancerous prostatic epithelial cells; its analysis typically follows radiological or spectrophotometric principles. Its role as a biomarker present in blood has been recently investigated and potential correlation between a concentration of GCPII and prostate cancer has been proposed. The wider inclusion of GCPII detection in clinical praxis limits mainly the time and cost per analysis. Here, we present a novel analytical nanosensor applicable to quantification of GCPII in human whole blood consisted of Fe3O4@Ag magnetic nanocomposite surface-functionalized by an artificial antibody (low-molecular-weight GCPII synthetic inhibitor). The nanocomposite allows a simple magnetic isolation of GCPII using external magnetic force and its consecutive determination by magnetically assisted surface enhanced Raman spectroscopy (MA-SERS) with a limit of detection 6 pmol. L-1. This method enables a rapid determination of picomolar concentrations of GCPII in whole human blood of healthy individuals using a standard addition method without a complicated sample pre-treatment.

Název v anglickém jazyce

Label-free determination of prostate specific membrane antigen in human whole blood at nanomolar levels by magnetically assisted surface enhanced Raman spectroscopy

Popis výsledku anglicky

Prostate cancer is one of the most common cancers among men and can in its later stages cause serious medical problems. Due to the limited suitability of current diagnostic biochemical markers, new biomarkers for the detection of prostate cancer are highly sought after. An ideal biomarker should serve as a reliable prognostic marker, be applicable for early diagnosis, and be applicable for monitoring of therapeutic response. One potential candidate is glutamate carboxypeptidase II (GCPII), also known as prostate specific membrane antigen (PSMA), which has a promising role for direct imaging. GCPII is considerably over-expressed on cancerous prostatic epithelial cells; its analysis typically follows radiological or spectrophotometric principles. Its role as a biomarker present in blood has been recently investigated and potential correlation between a concentration of GCPII and prostate cancer has been proposed. The wider inclusion of GCPII detection in clinical praxis limits mainly the time and cost per analysis. Here, we present a novel analytical nanosensor applicable to quantification of GCPII in human whole blood consisted of Fe3O4@Ag magnetic nanocomposite surface-functionalized by an artificial antibody (low-molecular-weight GCPII synthetic inhibitor). The nanocomposite allows a simple magnetic isolation of GCPII using external magnetic force and its consecutive determination by magnetically assisted surface enhanced Raman spectroscopy (MA-SERS) with a limit of detection 6 pmol. L-1. This method enables a rapid determination of picomolar concentrations of GCPII in whole human blood of healthy individuals using a standard addition method without a complicated sample pre-treatment.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

10403 - Physical chemistry

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Analytica Chimica Acta

ISSN

0003-2670

e-ISSN

—

Svazek periodika

997

Číslo periodika v rámci svazku

January

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

11

Strana od-do

44-51

Kód UT WoS článku

000415334500006

EID výsledku v databázi Scopus

2-s2.0-85033995055